go
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
lab refresh outlook go
refresh lab outlook launch coverag lab market underweight rate subsector
under-perform rate lh thesi pama cut like off-set tailwind manag
care network opportun pama cut would extend dynam yet appreci lab
outperform modestli sinc launch vs xlv attribut combin stabil
fundament post difficult lack exposur hc drug price reform propos optim market share gain
stick rate discuss depend guidanc shake set-up could get
summari thesi continu see consensu ep estim high coupl week next
year rather next decad believ diverg becom increasingli relev valuat sensit analysi
indic group would need trade premium market price-to-earnings multipl drive meaning out-performance
difficulti justifi mid-teen lab revenu come patient pay remain risk rel hc subsector
econom growth eventu slow market share gain remain real opportun larg factor
estim pace uncertain
set-up lh report result provid guidanc februari base last year lh appear
like report guid think compani may also use opportun calibr expect
pama cut still dont appear fulli reflect consensu estim think leav consensu estim
high pama fulli relief pama would becom upside-onli opportun allow greater focu
organ inorgan opportun
lh diagnost margin investor gener skeptic lh guidanc diagnost margin flat slightli
make earn bridg work get y/i magnitud improv vs estim
give us paus factor potenti new ceo conservat
estim chang reduc lh ep estim higher contribut
start off-set increment caution conservat margin revis ep estim
consensu visibl remain low
valuat lab trade consensu ep multipl rel valuat in-lin
year averag averag howev note consensu ep lab trade in-lin w/
rel valuat differ vs driven slower ep growth lab rel market
compani data factset wolf research llc
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
laboratori corp america lh year-end price rel price dividend rel dividend total rel analyst analyst analyst lab maintain market underweight rate reason avoid
reason avoid
consensu estim high pama
valuat like barrier out-performance
weak organ growth depend cut
larg spoken averag upsid capit deploy
poorli posit econom slowdown
reason
provid like gain share time
pama may lead industri consolid
exposur healthcar debat
compani data factset wolf research llc
lab refresh lab outlook go
tabl content
overview tabl content
make chang estim lh today note
minor model tweak
lh ep unchang ep lower
diagnost increas contribut better reflect materi q/q increas expect annual contribut
consensu y/i revenu growth appear fairli conserv light expect
covanc reduc margin improv assumpt
factset wolf research llc
lab consensu estim revis
show consensu estim revenu ep chang sinc end
revenu estim decreas modestli decreas compani
ep estim decreas respect
lh ep estim decreas
factset wolf research llc
ep bridg
ep bridg
factset wolf research llc
organ volum growth current unusu high move part
show decomposit organ volum growth break estim core organ growth factor
like manag care network chang unusu contract gains-to-loss weather calendar
bar repres posit axi neg axi factor line repres total growth
organ volum growth remain above-averag expect deceler vs
compani materi wolf research llc
lh ep bridg
lh ep bridg
factset wolf research llc
organ volum growth current unusu high move part
show decomposit organ volum growth break estim core organ growth factor
like manag care network chang unusu contract gains-to-loss weather calendar
bar repres posit axi neg axi factor line repres total growth
expect lh organ volum growth improv move past headwind network chang
compani materi wolf research llc
volum growth annual basi network access impactdtc consumercapit contract winsweathercalendarreport organ lh diagnost margin comment call
gener rule direct think share other preliminari review overal
diagnost busi anoth year pama ahead good news manag care impact
essenti number obvious start within first coupl month essenti rel flat year-on-year
beacon non-renew would expect diagnost plu minu would flat margin
look lh cfo glenn eisenberg confer call
obvious acquisit come lower margin synergi realiz improv margin also
continu impact carry-ov addit initi within launchpad ii program
off-set margin pressur experienc glenn said annual manag care
contract chang basic januari februari put take end day feel confid
flat slightli realist view margin diagnost former lh ceo david king
compani materi wolf research llc
given loss beaconlb contract florida lh commun slightli outlook margin
like hold margin flat
make earn bridg work get y/i magnitud improv vs
lh diagnost margin bridg
factset wolf research llc
show covanc revenu growth ebit growth ebit margin estim note
revenu growth includ fairli meaning contribut leav organ growth msd/hsd rang
model organ revenu growth envigo deal ad growth
continu model modest margin expans annual note lh covanc
launchpad program conclud
quarterli book-to-bil ratio somewhat inconsist recent quarter although fairli strong
cdd quarterli book-to-bil ratio
compani materi wolf research llc
note comparison impact chilltern acquisit
note book-to-bil exclud one month envigo acquisit book
marginrevenu ebit growthrevenu growthebit growthebit lh quick thought sanofi covanc exposur
monday sanofi cover global pharmaceut analyst tim anderson announc would discontinu
research diabet cardiovascular expect gener save combin lower
spend depriorit busi procur initi manufactur organiz product
sanofi histor one covanc largest custom compani enter strateg
allianc announc also includ asset transfer agreement site franc england
year term renew expir effect
base size servic compon allianc last size sanofi growth sinc
would estim sanofi make less covanc revenu today
continu refin exposur estim wouldnt surpris covanc cancel rate elev
base sanofi depriorit therapeut area pressur net book-to-bil revenu growth rate modestli
also note servic contract approach end date expect visibl renew rfp process
becom area focu investor
estim exposur lh covanc busi sanofi
compani materi wolf research llc
sanofi eur compani metric reflect wr pharma team publish estimateaverag eur usd factsetsanofi revenu disclos estim base sanofi growth rate usdasset transfer disclos extend initi term end effect compani metric reflect wr publish estimatesanofi revenu covanc revenu sanofi lh covanc spin-off scenario
lh thought sum-of-the-part math
investor frequent bring lh
appear get much credit higher-
think part issu sum-of-
the-part appear action
term spin-off optimist
scenario produc modest upsid
lay scenario split lh two
remainco lab busi retain lh
unalloc corpor cost spinco
adjust spinco cro busi
revers synergi
realiz post lh acquisit covanc
headwind covanc
assum remainco lab busi trade
line spinco cro
busi trade line iclr arriv
note covanc oper margin
peer averag report today
despit healthi amount
cost alloc segment
factset wolf research llc
ytd rel stock perform dec
rel price return xlv
factset wolf research llc
relativelh rel ytd rel perform vs chang liber candid poll
took rel perform lab xlv compar chang poll group liber
candid compris warren sander harri yang
benchmark bi-weekli poll year-end track cumul gain sinc time
analysi produc correl coeffici
ytd lab rel stock perform vs chang liber candid poll
realclearpolit wolf research llc
rel xlvytd chang liber candid poll lab exposur healthcar debat
clinic lab littl exposur key current
debat health care center medicare-for-
prescript drug spend pharmaceut suppli
chain rebat risk disrupt via new entrant
spend lab servic hospit physician make
health care spend help industri keep
lab uniqu coupl interest way
one place health care neg price
growth commerci payment rate well
medicar rate least pama fulli implement
pay-for would wildcard argument
made lab servic would becom best hous bad
neighborhood medicar enact
wolf research llc
hospit privat residenti medic lab short interest
factset wolf research llc
lab price-to-earnings valuat past year dec
lab absolut price-to-earnings present
lab rel price-to-earnings present
factset wolf research llc
lab ev/ebit valuat past year dec
lab absolut ev/ebit present
lab rel ev/ebit present
factset wolf research llc
lab ev/ebitda valuat past year dec
lab absolut ev/ebitda present
lab rel ev/ebitda present
factset wolf research llc
valuat sensit analysi indic group would need trade premium market price-to-earnings multipl drive
meaning out-performance difficulti justifi
note use ev ebit valuat multipl compani produc lower rel price-to-earnings multipl
lh given lh materi higher leverag
compani data factset wolf research llc
compani data factset wolf research llc
current rel rel rel rel rel price-to-earnings price-to-earnings price dividiend dividend rel rel ev ebit rel ev ebit rel ev ebit rel ev ebit ev ebit enterpris debt prefer conv debt unconsolid equiti count rel price lh price develop
compani data factset wolf research llc
laboratori corp america lh current rel rel rel rel rel price-to-earnings price-to-earnings price dividiend dividend rel corp america rel ev ebit rel ev ebit rel ev ebit rel ev ebit ev ebit enterpris debt prefer conv debt unconsolid equiti count rel price protect access medicar act pama
background protect access medicar act pama
sinc medicar part paid diagnost test base fee schedul medicar part cover outpati
treatment servic part cover inpati care
prior clinic laboratori fee schedul clf base histor laboratori charg
adjust annual inflat factor
congress pass protect access medicar act pama revis medicar part
payment system diagnost test substitut market-bas approach clf
section pama requir applic laboratori report test volum reimburs paid privat payor
center medicar medicaid servic order calcul new reimburs rate
hh oig wolf research llc
background protect access medicar act pama
ultim definit applic laboratori left defin applic laboratori use key
characterist major medicar revenu come medicar clinic laboratori fee schedul
servic bill medicar nation provid identifi npi
importantli hospit laboratori bill medicar use npi instead use hospit exist npi
effect exclud hospit outreach lab privat payor data collect
hospit outreach lab significantli better price independ lab given signific market power health
system remov data collect mean new payment system base almost entir
importantli pama contain provis phase reimburs cut annual reimburs
decreas given test cap threshold increas begin
payercommercialcommercialcommercialmedicar part bsettinghospit labindepend labaverageal settingstest part bsettinghospit labindepend labaverageal settingstest current pama baselin includ cut
proprietari analysi pama rate submiss data indic anoth fairli signific medicar reduct
pama cut fairli well understood major test potenti anoth
signific neg impact remain somewhat underappreci
note commerci rate due remeasur calcul medicar clf rate effect
chang definit applic lab includ hospit outreach lab
wr estim medicar clf payment reduct
reflect consensu
fulli reflect
compani data factset wolf research llc
novemb investor day outlin expect pama cut steer away
provid quantif
base current rate would expect anoth hsd cut clf revenu
recent ndr compani note pama cut expect gener consist
basi consist analysi
chang definit applic lab sens doesnt expect would drive much
chang rate rate remeasur current schedul given challeng hospit face compli
chart show estim y/i reduct clf revenu dgx pama guidanc
headwind would estim base anchor dgx cut
pama outlook overlaid w/ wr analysi pama rate impli cut
note pama outlook come compani novemb investor day slide quantif provid
compani materi wolf research llc
revenu impact million cut clf rate pama outlook pama outlook anchor y/i cut wr analysi potenti pama relief lab act
lab industri pursu relief pama reimburs cut court challeng
legisl
lab act would delay data collect next round clinic laboratori fee
schedul clf rate
would like result hospit outreach program abl report
data although sens materi shift vs current schedul collect
interestingli delay would like result current data use
calcul clf rate believ would result similar headwind
howev rate could potenti increas place
captur rate hospit outreach lab improv downward pressur
commerci rate time-frame
outlook inclus lab act year-end budget legisl remain uncertain given
trade group lab industri challeng definit applic laboratori court
ground contrari languag legisl intent pama exclud
virtual hospit lab
judg jackson district court initi rule industri lawsuit
view languag within pama preclud judici review therefor find court
subject matter jurisdict
juli court appeal district columbia rule favor lab industri
sent american clinic laboratori associ acla lawsuit challeng
implement pama back district court rule actual thrust
lawsuit whether definit applic laboratori conflict congression intent
payment rate meant calcul
octob acla file motion summari judgment
novemb hh file opposit acla motion summari judgment along
cross-mot summari judgment
decemb acla file repli support motion summari judgment
opposit hhss cross-mot summari judgment
januari hh file repli support cross-mot summari judgment
industri like know legal challeng success prospect
cure remain highli uncertainti could take signific time clariti emerg
note desir outcom lab industri would leav medicar rate therefor
profit commerci rate profit independ lab unusu
dynam vs almost healthcar reimburs medicar typic view
sampl frequent ask question provid bulletin
launch newli
network pln includ
laboratori
would expect pln
clearli subset exist
separ network
member still use lab
pln benefit choos lab
pln may includ shorter wait
time servic on-line schedul
patient servic center higher
qualiti care lower cost
expect physician refer
lab pln see prompt turn-
around time lab result ease-of-
use order lab electron
easi access physician-to-lab
assum market share gain
pln allow organ
volum growth remain modestli
long-term averag
unitedhealthcar wolf research llc
specul unitedhealthcar start introduc plan featur pln member abl use
pln lab out-of-pocket cost
laboratori econom report recent issu large-group fully-insur member il ia ks mi mo
ne ok tx out-of-pocket respons lab servic util pln
thought process plan sponsor lower cost despit pay entir reimburs amount
partner unitedhealthcar move test volum high-valu lab like quest high-cost
hospit out-of-network lab
unitedhealthcar began offer product member out-of-pocket charg laboratori test
major fulli insur live select state octob
unitedhealthcar also make lab save program avail self-insur employ group
begin earn call
excerpt laboratori econom novemb issu unit pln
unitedhealthcar wolf research llc
get better sens rel cost differ plan member use unit ralli tool record cost
out-of-pocket insur lab test avail perform quest labcorp enzo non-pln
northwel health hospit outreach lab non-pln
analysi found median cost share differenti per test dgx/lh vs northwel like less
pln lab move cost-shar across plan type median differenti per test vs northwel would still
less
pln lab move cost-shar across plan type median differenti per test vs northwel would still
less
fair would note averag higher median attract out-of-
pocket cost much higher member hit deduct year
far lab network would typic out-of-pocket determin plan benefit design whether high
deduct plan sort co-insur wont zero think averag requisit
somewher typic patient respons time indiscern respons
time might healthcar dollar balanc paid compani math
recalcul split insur pocket
unitedhealthcar wolf research llc
averageinsureroopinsureroopinsureroopinsureroopblood stool stool split insur out-of-pocketdgxlhdgxlhenzonorthwel unitedhealthcar prefer lab network physician incent
benefit plan member fairli easi understand although depend member awar
potenti also willing compar cost physician incent also highli critic given signific
major volum come physician offic compani patient servic center
signal financi incent physician util lab pln compani
will provid much way specif
physician reimburs alreadi vari base degre in-network vs out-of-network referr
sens pln would add anoth layer type framework
want go best lab great price also zero out-of-pocket simpl
decis patient import also unit talk also
thing around incent physician well patient-driven initi
let talk unit end
obvious imagin lot work field commerci sale forc
make sure physician awar realli good patient physician
prioriti patient owner anybodi els know good thing
patient like earn call
unitedhealthcar wolf research llc
organ volum growth current unusu high move part
show decomposit organ volum growth break estim core organ growth factor
like manag care network chang unusu contract gains-to-loss weather calendar
bar repres posit axi neg axi factor line repres total growth
except leap year expect fairli similar organ growth group whole
compani materi wolf research llc
compani data wolf research llc
compani data wolf research llc
compani data wolf research llc
